Phyto Chem (I) (524808)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Book value of ₹14.99 per share provides a tangible asset cushion for the ₹13 Cr market cap.
• ROCE positive at 3.27% suggests operations still generate some return on capital employed despite reported losses.
• Latest quarter net loss of ₹-0 Cr on ₹3 Cr sales indicates the loss may be narrowing.
• Tiny market cap means a modest absolute improvement in earnings could have an outsized effect on valuation.

Concerns

• ROE at -44.67% and profit growth at -131.58% show severe shareholder value destruction.
• Sales are declining -18.63%, and P/E of 0 confirms there are no current earnings to justify the price.
• P/B of 2.01 means paying a large premium over book value for a loss-making, financially weak business.
• Piotroski F-Score of 3/9, zero dividend, and missing promoter/debt data make this highly opaque.

AI Analysis

At ₹30.08, Phyto Chem is a ₹13 crore market-cap pesticide business. My first test is business quality: agrochemicals are commodity-like, with pricing power dictated by monsoon, crop cycles, and competitors. Nothing in these numbers suggests a durable moat. The second test is financial health, and that is poor. Book value is ₹14.99, yet I am being asked to pay 2.01 times book. Return on equity is -44.67%, meaning the enterprise is destroying shareholder capital at an alarming rate. Sales have fallen 18.63% and profit growth is -131.58%; the P/E is meaningless because earnings are negative. The Piotroski F-Score of 3/9 is a clear warning: this company fails most basic financial-strength tests. There is no dividend to reward a patient holder. On the positive side, ROCE is 3.27%, so the underlying capital employed still earns something before interest. The latest quarter shows sales of ₹3 crore and a net loss of only ₹-0 crore, a hint that the bleeding may be slowing. Book value of ₹14.99 gives a tangible asset floor, and at ₹13 crore market capitalization even a small absolute profit recovery would move the shares. But Graham taught me to buy with a margin of safety. Paying ₹30 for a business earning -44.67% on equity, with declining sales, no promoter-disclosure comfort, and insufficient data for a FairStock score, is not value investing. It is hope. I would only revisit this as a turnaround speculation if quarterly losses turn to consistent profits, F-Score improves, and the debt/equity and promoter holdings are disclosed. Until then, this is a 'no'.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer